- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x 85T: 4-amino-1-{2-cyano-2-deoxy-5-O-[(S)-hydroxy{[(S)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-D-arabinofuranosyl}pyrimidin-2(1H)-one(Non-covalent)
- 4 x DTP: 2'-DEOXYADENOSINE 5'-TRIPHOSPHATE(Non-covalent)
DTP.2: 20 residues within 4Å:- Chain A: R.257, F.261, R.276, K.278, N.282, K.447
- Chain B: V.41, I.42, N.43, H.49
- Chain C: V.80, F.81, P.82, I.249, R.296, H.300, K.301, V.302
- Ligands: MG.9, GTP.11
20 PLIP interactions:11 interactions with chain A, 7 interactions with chain C, 2 interactions with chain B- Hydrogen bonds: A:R.257, A:N.282, A:N.282, B:N.43, B:N.43
- Salt bridges: A:R.257, A:R.276, A:K.278, A:K.278, A:K.278, A:K.447, C:H.300, C:H.300, C:K.301, C:K.301, C:K.301
- pi-Cation interactions: A:R.257, A:R.257
- Hydrophobic interactions: C:V.80, C:F.81
DTP.7: 18 residues within 4Å:- Chain A: V.41, I.42, N.43, H.49
- Chain B: R.257, F.261, R.276, K.278, N.282, K.447
- Chain D: V.80, F.81, R.296, H.300, K.301, V.302
- Ligands: MG.3, GTP.18
20 PLIP interactions:11 interactions with chain B, 7 interactions with chain D, 2 interactions with chain A- Hydrogen bonds: B:R.257, B:N.282, B:N.282, A:N.43, A:N.43
- Salt bridges: B:R.257, B:R.276, B:K.278, B:K.278, B:K.278, B:K.447, D:H.300, D:H.300, D:K.301, D:K.301, D:K.301
- pi-Cation interactions: B:R.257, B:R.257
- Hydrophobic interactions: D:V.80, D:F.81
DTP.10: 20 residues within 4Å:- Chain A: V.80, F.81, P.82, I.249, R.296, H.300, K.301, V.302
- Chain C: R.257, F.261, R.276, K.278, N.282, K.447
- Chain D: V.41, I.42, N.43, H.49
- Ligands: MG.14, GTP.16
23 PLIP interactions:3 interactions with chain D, 13 interactions with chain C, 7 interactions with chain A- Hydrogen bonds: D:N.43, D:N.43, C:R.257, C:N.282, C:N.282
- Water bridges: D:K.40, C:R.276, C:R.276
- Salt bridges: C:R.257, C:R.276, C:K.278, C:K.278, C:K.278, C:K.447, A:H.300, A:H.300, A:K.301, A:K.301, A:K.301
- pi-Cation interactions: C:R.257, C:R.257
- Hydrophobic interactions: A:V.80, A:F.81
DTP.17: 19 residues within 4Å:- Chain B: V.80, F.81, I.249, R.296, H.300, K.301, V.302
- Chain C: V.41, I.42, N.43, H.49
- Chain D: R.257, F.261, R.276, K.278, N.282, K.447
- Ligands: GTP.5, MG.13
20 PLIP interactions:7 interactions with chain B, 11 interactions with chain D, 2 interactions with chain C- Hydrophobic interactions: B:V.80, B:F.81
- Salt bridges: B:H.300, B:H.300, B:K.301, B:K.301, B:K.301, D:R.257, D:R.276, D:K.278, D:K.278, D:K.278, D:K.447
- Hydrogen bonds: D:R.257, D:N.282, D:N.282, C:N.43, C:N.43
- pi-Cation interactions: D:R.257, D:R.257
- 8 x MG: MAGNESIUM ION(Non-covalent)
MG.3: 4 residues within 4Å:- Chain A: K.40
- Chain B: K.447
- Ligands: DTP.7, GTP.18
No protein-ligand interaction detected (PLIP)MG.4: 4 residues within 4Å:- Chain A: R.130, D.233, K.236
- Ligands: 85T.1
3 PLIP interactions:1 interactions with chain A, 2 Ligand-Water interactions- Metal complexes: A:D.233, H2O.1, H2O.1
MG.8: 4 residues within 4Å:- Chain B: R.130, S.226, D.233
- Ligands: 85T.6
4 PLIP interactions:1 interactions with chain B, 3 Ligand-Water interactions- Metal complexes: B:S.226, H2O.1, H2O.1, H2O.1
MG.9: 4 residues within 4Å:- Chain A: K.447
- Chain B: K.40
- Ligands: DTP.2, GTP.11
No protein-ligand interaction detected (PLIP)MG.13: 3 residues within 4Å:- Chain C: K.40
- Ligands: GTP.5, DTP.17
No protein-ligand interaction detected (PLIP)MG.14: 4 residues within 4Å:- Chain C: K.447
- Chain D: K.40
- Ligands: DTP.10, GTP.16
No protein-ligand interaction detected (PLIP)MG.15: 3 residues within 4Å:- Chain C: D.233, K.236
- Ligands: 85T.12
No protein-ligand interaction detected (PLIP)MG.20: 3 residues within 4Å:- Chain D: D.233, K.236
- Ligands: 85T.19
No protein-ligand interaction detected (PLIP)- 4 x GTP: GUANOSINE-5'-TRIPHOSPHATE(Non-covalent)
GTP.5: 16 residues within 4Å:- Chain B: Y.79, V.80, V.302, R.375, K.379
- Chain C: K.40, V.41, I.42, I.60, D.61, Q.66, R.69, F.89
- Chain D: K.447
- Ligands: MG.13, DTP.17
14 PLIP interactions:5 interactions with chain B, 7 interactions with chain C, 2 interactions with chain D- Hydrogen bonds: B:R.375, C:V.41, C:Q.66, C:R.69
- Salt bridges: B:R.375, B:K.379, B:K.379, C:K.40, C:K.40, C:K.40, C:D.61, D:K.447, D:K.447
- pi-Cation interactions: B:R.375
GTP.11: 17 residues within 4Å:- Chain A: K.447
- Chain B: K.40, V.41, I.42, V.57, I.60, D.61, Q.66, R.69, F.89
- Chain C: Y.79, V.80, V.302, R.375, K.379
- Ligands: DTP.2, MG.9
15 PLIP interactions:8 interactions with chain B, 5 interactions with chain C, 2 interactions with chain A- Hydrogen bonds: B:K.40, B:V.41, B:Q.66, B:R.69, C:R.375
- Salt bridges: B:K.40, B:K.40, B:K.40, B:D.61, C:R.375, C:K.379, C:K.379, A:K.447, A:K.447
- pi-Cation interactions: C:R.375
GTP.16: 15 residues within 4Å:- Chain A: Y.79, V.80, V.302, R.375
- Chain C: K.447
- Chain D: K.40, V.41, I.42, I.60, D.61, Q.66, R.69, F.89
- Ligands: DTP.10, MG.14
15 PLIP interactions:9 interactions with chain D, 4 interactions with chain A, 2 interactions with chain C- Hydrogen bonds: D:V.41, D:Q.66, D:R.69, A:R.375
- Water bridges: D:K.40, D:K.40
- Salt bridges: D:K.40, D:K.40, D:K.40, D:D.61, A:R.375, A:K.379, C:K.447, C:K.447
- pi-Cation interactions: A:R.375
GTP.18: 17 residues within 4Å:- Chain A: K.40, V.41, I.42, V.57, I.60, D.61, Q.66, R.69, F.89
- Chain B: K.447
- Chain D: Y.79, V.80, V.302, R.375, K.379
- Ligands: MG.3, DTP.7
14 PLIP interactions:7 interactions with chain A, 2 interactions with chain B, 5 interactions with chain D- Hydrogen bonds: A:V.41, A:Q.66, A:R.69, D:R.375
- Salt bridges: A:K.40, A:K.40, A:K.40, A:D.61, B:K.447, B:K.447, D:R.375, D:K.379, D:K.379
- pi-Cation interactions: D:R.375
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rothenburger, T. et al., Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res (2021)
- Release Date
- 2021-10-27
- Peptides
- Deoxynucleoside triphosphate triphosphohydrolase SAMHD1: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x 85T: 4-amino-1-{2-cyano-2-deoxy-5-O-[(S)-hydroxy{[(S)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-D-arabinofuranosyl}pyrimidin-2(1H)-one(Non-covalent)
- 4 x DTP: 2'-DEOXYADENOSINE 5'-TRIPHOSPHATE(Non-covalent)
- 8 x MG: MAGNESIUM ION(Non-covalent)
- 4 x GTP: GUANOSINE-5'-TRIPHOSPHATE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rothenburger, T. et al., Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res (2021)
- Release Date
- 2021-10-27
- Peptides
- Deoxynucleoside triphosphate triphosphohydrolase SAMHD1: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D